Main recent clinical trials in pulmonary arterial hypertension with either negative result or tolerability/safety issues
| Study/compound(s) | 阶段 | End-point: result | Formal presentation [ref.] | Published [ref.] |
| ASA-STAT:阿司匹林和辛伐他汀 | 2 | 6MWD: lack of efficacy | Yes | Yes [103] |
| ARROW: selonsertib (ASK-1 inhibitor) | 2 | 6MWD: lack of efficacy | Yes [62] | No |
| Cicletanine (antihypertensive with vasorelaxant and diuretic properties) | 2 | PVR: lack of efficacy | Yes [104] | No |
| Aviptadil (vasoactive intestinal peptide) | 2 | PVR: lack of efficacy | Yes [105] | No |
| IMPRES: imatinib (tyrosine kinase inhibitor) | 3 | 6随钻测量:及tive tolerability and safety issues | Yes | Yes [45] |
| Terguride (partial dopamine agonist and serotonin receptor antagonist) | 2 | 6MWD: lack of efficacy | Yes [68] | No |
| LIBERTY: ubenimex (leukotriene B4 inhibitor) | 2 | PVR: lack of efficacy | No | No |
6MWD: 6-min walk distance; ASK1: apoptosis signal-regulating kinase 1; PVR: pulmonary vascular resistance.